- Home
- VRDN vs RXRX Comparison
VRDN vs RXRX Comparison
Compare VRDN & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | RXRX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRDN | RXRX |
|---|---|---|
| Price | $28.69 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $36.20 | $7.32 |
| AVG Volume (30 Days) | 2.6M | ★ 22.9M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | N/A | ★ N/A |
| Revenue | $5,706,000.00 | ★ $74,681,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $878.45 | $49.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.92 |
| 52 Week Low | $13.18 | $2.77 |
| 52 Week High | $34.29 | $5.24 |
Technical Indicators
Market Signals| Indicator | VRDN | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 78.24 | 45.15 |
| Support Level | $26.31 | $2.90 |
| Resistance Level | $30.79 | $3.66 |
| Average True Range (ATR) | 1.41 | 0.31 |
| MACD | 0.71 | -0.05 |
| Stochastic Oscillator | 89.65 | 13.70 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.